The future of erectile dysfunction (Ed)

Archivos Espanoles de Urologia

Volumn 63, Issue 8, 2010, Pages 740-747

  Porst, Hartmut ^a  

^a Standards Committee for Sexual Medicine   (Germany)

Author keywords

Erectile dysfunction; Gene therapy; Guanylate cyclase activators; Kinase inhibitors; Melanocortin agonists; Non responders; PDE 5 inhibitors; RhoA

Indexed keywords

ARTICLE; ERECTILE DYSFUNCTION; FORECASTING; GENE THERAPY; HUMAN; MALE;

ERECTILE DYSFUNCTION; FORECASTING; GENE THERAPY; HUMANS; MALE;

EID: 78149263062     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jiann BP, Yu CC, Su CC, Tsai JY.: Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res. 2006;18(2):146-149
2. Souverein PC, Egberts ACG, Meuleman EJH, Urquhart J, Leufkens HGM (2002 Incidence and determinants of sildenafil discontinuation: the Dutch cohort of sildenafil users. Int J Impotence Res 14: 259-265
3. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978-2984
4. Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. International Journal of Obesity advance online publication 20 April 2010.
5. Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: Results of a randomized controlled study. J Sex Med 2010, published online 30 March.
6. Porst H. Oral Pharmacotherapy of Erectile Dysfunction (ED).In Porst H,Buvat J: Standards Praxis of Sexual Medicine. Blackwell Publishing, 2006,pp 75-93.
7. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral,selective phosphodiesterase type 5 inhibitor,in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impotence Res 2001,13,192-199
8. Brock G B, McMahon C G, Chen K K, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol, 2002 ,168,1332-1336
9. Hellstrom WJG, Gittelman M, Karling G, et al. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl, 2002; 23,763-771
10. Glina S, Fonseca GN, Bertero EB, Damião R, Rocha LC, Jardim CR, Cairoli CE, Teloken C, Torres LO, Faria GE, da Silva MB, Pagani E. Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial. J Sex Med. 2010,7: 1928-1936.
11. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med. 2008;5(11):2672-2680
12. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC.: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946-953
13. Park HJ, Park JK, Park K, Min K, Park NC: Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial. J Sex Med. 2010 Apr 20. Epub ahead of print
14. Ledda A, Belcaro G, Cesarone MR, Dugall M, Schönlau F: Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010 Feb 22
15. Gentile V, Antonini G, Antonella Bertozzi M, Dinelli N, Rizzo C, Ashraf Virmani M, Koverech A: Effect of propionyl-L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin. 2009;25(9):2223-2228
16. Freitas FC, Nascimento NRF, Cerqueira JBG Morais, MEA Regadas, RP, Gonzaga-Silva LF: Yohimbine relaxes the human corpus cavernosum through a nondrenergic mechanism involving the activation of K+ATP-dependent channels. Int J Impot Res. 2009; 21(6):356-361
17. Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E : Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51-60.
18. Miner M, Billups KL: Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med. 2008;5(5):1066-1078
19. Gur S, Kadowitz PJ, Hellstrom WJ: Exploring the potential of no-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile. Curr Pharm Des. 2010; 16(14):1619-1633
20. Stasch JP, Hobbs AJ: NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;(191):277-308
21. Mills T M, Chitaley K, Lewis R W. Vasocons-triction in erectile physiology. Int. J. Impotence Res., 2001; 13, Suppl. 5, S29-S34
22. Chitaley K, Webb RC, Mills TM The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of Rho-kinase and their potential role in the erectile response-Int J Impotence Res 2003, 15: 105-109
23. Wilkes N, White S, Rajasekaran M: PDE-V inhibitors synergize Rho-kinase antagonism and enhance erectile response in male hypertensive rats. J Uro, 2003; 169 No 4 Suppl, 360:1346
24. Wilkes N, White S, Cosgrove DJ, Rajasekaran M: Y-27632,an inhibitor of Rho-kinase, improves erectile response in male hypertensive rats. J Urol 2002; 167 No 4 Suppl, 238: 935
25. Zheng Y, Chang S, Wein AJ et al: Upregulation of Rho-kinase in a human corpus cavernosum smooth muscle cell line in response to hypoxia. J Urol 2004; 171 Suppl 376 Abstr.1429
26. Liu J, Jinhan F, Rao K, Song G, Yuan H, Chen R, Wang T, Wang S, Yang W, Ye Z. Elevated RhoA/Rho-Kinase activity in the hyperlipidemic rabbit penis: Mechanism for hyperlipidemia-associated erectile dysfunction.J Uerol. 2010,183,No.4 Suppl.,abstract 712.
27. Dai Y, Chitaley K, Webb RC et al: Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impotence Res, 2004;16,294-8.28)
28. Hatzimouratidis K, Hatzichristou DG: Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-250
29. Porst H: Future Aspects of Pharmacotherapy in ED In. Porst, H. and Buvat, J. (eds), Standard Practice in Sexual Medicine Blackwell Publishing, 2006;pp 109-114
30. Sezen SF, Lagoda G, Burnett AL: Role of immunophilins in recovery of erectile function after cavernous nerve injury. J Sex Med. 2009;6 Suppl 3:340-346
31. Mulhall J, Klein E, Slawin K, Scardino PT: Tacrolimus (FK506)as a neuromudlator in the radical prostatectomy population: A multicenter,double- blind,randomized,placebo-controlled trial. J Urol 2010;183,No.4 Suppl. Abstract 1373
32. Angeloni N, Bond C, Zhang S, Harrington D, McKenna K, Stupp S, Podlasek C: Cavernous Nerve Regeneration by Sonic Hedgehog.J Urol 2010;183,No.4Suppl. abstract 876.
33. Rosen RC, Diamond, LE, Earle DC et al: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist , in healthy male subjects and in patients with inadequate response to Viagra®. Int J Impotence Res 2004; 16, 135-142
34. Wessels H, Padma-Nathan H, Rajfer J, et al. At-home efficacy of an intranasal administered melanocortin receptor agonist, PT-141, in men with erectile dysfunction (ED). J Urol 2004, 171 Suppl, 316 Abstr 1197
35. Hellstrom W.J.G: Future Treatment Aspects of ED: Gene Therapy and Tissue Engineering. In: Porst, H. and Buvat, J. (eds), Standard Practice in Sexual Medicine Blackwell Publishing, 2006,pp 115.
36. Lysiak JJ, Kavoussi PK, Ellati RT, Steers WD, Annex BH: Angiogenesis therapy for the treatment of erectile dysfunction. J Sex Med 2010, published online 26 April.
37. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G: hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther.2006;17:1165-1176
38. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G: Plasmid- based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial.Isr Med Assoc J 2007;9:143-146
39. Lin G, Banie L, Ning H, Bella AJ, Lin CS, Lue TF. : Potential of adipose-derived stem cells for treatment of erectile dysfunction. J Sex Med. 2009;6 Suppl 3:320-327
40. Nolazco G, Kovanecz I, Vernet D, Gelfand RA, Tsao J, Ferrini MG, Magee T, Rajfer J, Gonzalez-Cadavid NF: Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int. 2008;101(9):1156-1164